

## Product datasheet for TP727539

## **Cynomolgus Recombinant Protein**

## **Product data:**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product Type:	Recombinant Proteins
Description:	Recombinant Cynomolgus B7-1/CD80 (C-6His)
Species:	Cynomolgus
Expression cDNA Clone or AA Sequence:	Val35-Asn242
Tag:	C-His
Buffer:	Lyophilized from a 0.2 um filtered solution of PBS, pH 7.4.
Note:	Recombinant Cynomolgus T-lymphocyte Activation Antigen CD80 is produced by our Mammalian expression system and the target gene encoding Val35-Asn242 is expressed with a 6His tag at the C-terminus.
Stability:	12 months from date of despatch
Summary:	Cynomologous Cluster of Differentiation 80, also called B7-1, is a member of cell surface immunoglobulin superfamily. It is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. CD80 plays key, yet distinct roles in the activation of T cells. B7-1/CD80 and B7-2/CD86, together with their receptors CD28 and CTLA4, constitute one of the dominant co-stimulatory pathways that regulate T- and B- cell responses. CD80 is mostly expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US